Search

Your search keyword '"Schalm, Stefanie"' showing total 32 results

Search Constraints

Start Over You searched for: Author "Schalm, Stefanie" Remove constraint Author: "Schalm, Stefanie"
32 results on '"Schalm, Stefanie"'

Search Results

1. Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma

3. P464: PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT-253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS.

5. Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the Treatment of Acute Myeloid Leukemia

6. Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer

7. Abstract 3934: KT-253, a highly potent and selective heterobifunctional MDM2 degrader for the treatment of wildtype p53 tumors with superior potency and differentiated biological activity compared to small molecule inhibitors (SMI)

8. Abstract 3328: Antitumor activity of BLU-945 and BLU-701 as single agents and in combination in EGFR L858R-driven models of NSCLC

9. Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

10. An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

11. BLU-701 tumour suppression and intracranial activity as a single agent and in combination with BLU-945 in models of non-small cell lung cancer (NSCLC) driven by EGFR mutations

14. Evaluation of PRKACA as a Therapeutic Target for Fibrolamellar Carcinoma

15. Abstract 1467: BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robust in vivo antitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC)

16. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

17. Abstract B127: Evaluating PRKACA as a therapeutic target for Fibrolamellar Carcinoma

18. 78 - BLU-701 tumour suppression and intracranial activity as a single agent and in combination with BLU-945 in models of non-small cell lung cancer (NSCLC) driven by EGFR mutations

20. Abstract 2296: IDH2 mutation induced histone and DNA hypermethylation is progressively reversed by small molecule inhibition

22. Molecular Mechanism of mTOR downstream signaling

23. Mutation Selective IDH Inhibitors Mediate Histone and DNA Methylation Changes

24. Abstract LB-164: IDH mutations and tumorgenicity

31. Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation.

32. Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma.

Catalog

Books, media, physical & digital resources